NEW YORK (GenomeWeb News) – Toxicology and genetics lab Physician's Choice Laboratory Services has acquired the CertNDx Bladder Cancer diagnostic testing assets from Predictive Biosciences for an undisclosed amount. The CertNDx Bladder Cancer Assay is a urine-based test that uses protein biomarkers and molecular DNA analysis to detect the presence or absence of urothelial cancer in patients presenting with hematuria. It stratifies patients based on their likelihood of bladder cancer and disease progression.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.